These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9266620)

  • 1. Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.
    Elkayam O; Yaron M; Zhukovsky G; Segal R; Caspi D
    Rheumatol Int; 1997; 17(2):49-53. PubMed ID: 9266620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
    Erhardt DP; Cannon GW; Teng CC; Mikuls TR; Curtis JR; Sauer BC
    Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1326-1335. PubMed ID: 30221485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
    Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.
    Dougados M; Combe B; Cantagrel A; Goupille P; Olive P; Schattenkirchner M; Meusser S; Paimela L; Rau R; Zeidler H; Leirisalo-Repo M; Peldan K
    Ann Rheum Dis; 1999 Apr; 58(4):220-5. PubMed ID: 10364900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis.
    Nisar M; Carlisle L; Amos RS
    Br J Rheumatol; 1994 Jul; 33(7):651-4. PubMed ID: 7912633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA
    Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis.
    Bhavsar SV; Movahedi M; Cesta A; Pope JE; Bombardier C;
    Joint Bone Spine; 2024 Jul; 91(4):105732. PubMed ID: 38583692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional DMARD options for patients with a suboptimal response to methotrexate.
    O'Dell J
    J Rheumatol Suppl; 2001 Jun; 62():21-6. PubMed ID: 11409154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.
    O'Dell JR
    Rheum Dis Clin North Am; 1998 Aug; 24(3):465-77. PubMed ID: 9710881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.
    Salaffi F; Carotti M; Cervini C
    Scand J Rheumatol; 1996; 25(1):16-23. PubMed ID: 8774550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.
    Haagsma CJ; van Riel PL; de Rooij DJ; Vree TB; Russel FJ; van't Hof MA; van de Putte LB
    Br J Rheumatol; 1994 Nov; 33(11):1049-55. PubMed ID: 7981992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
    van Jaarsveld CH; Jahangier ZN; Jacobs JW; Blaauw AA; van Albada-Kuipers GA; ter Borg EJ; Brus HL; Schenk Y; van Der Veen MJ; Bijlsma JW
    Rheumatology (Oxford); 2000 Dec; 39(12):1374-82. PubMed ID: 11136881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.
    Clegg DO; Dietz F; Duffy J; Willkens RF; Hurd E; Germain BF; Wall B; Wallace DJ; Bell CL; Sleckman J
    J Rheumatol; 1997 Oct; 24(10):1896-902. PubMed ID: 9330929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.